Home / About Us
Home / Innovation

Development and Innovationfor the Future

Pipeline

At kanghong, we aim to translate R&D innovations for fighting diseases and extending patients’ lives.
Now, we are advancing that R&D innovation by investing in nearly a dozen clinical and pre-clinical programs spanning ophthalmology, CNS, oncology and common disease.

Clinical Trials

We are committed to translating R&D innovations to meet clinical needs and improve patient health.

KH631
KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector. clinicaltrials.gov
KH617
 KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection. clinicaltrials.gov
KH110
KH110 is an innovative Chinese patent medicine for the treatment of Alzheimer's disease. chinadrugtrials.org
KH903
Gastric Cancer II Project, completed the trial 2 months ahead of schedule and received IDMC recommendations. One of the subjects had a progression-free survival of 14 months.chinadrugtrials.org
KH801
The unique molecular design of antibody drugs is in the first echelon of research and development in the world.
KH607
It will meet the urgent clinical need for antidepressants that act faster and have a wider range of patients, and has shown good pharmacokinetic properties in mice, dogs and monkeys.
KH629
It is developed for the huge potential of non-alcoholic fatty liver disease drug market, and has obvious advantages in head-to-head research with positive controls.